MedTrace Logo

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

NCT00314132 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2004

Last updated 2012-12-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

Conditions

Interventions

BIOLOGICAL

ChimeriVax-JE, Japanese Encephalitis vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

0.9% Saline

0.5 mL, Subcutaneous

Sponsors & Collaborators

Principal Investigators

  • Steven G Hull, MD · Vince and Associates Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00314132 on ClinicalTrials.gov